Literature DB >> 11949704

Do neuropsychological tests detect preclinical Alzheimer's disease: individual-test versus cognitive-discrepancy score analyses.

Mark W Jacobson1, Dean C Delis, Mark W Bondi, David P Salmon.   

Abstract

Attempts to identify cognitive markers of a preclinical phase of Alzheimer's disease (AD) have yielded inconsistent findings. The problem may stem in part from methodologies that are insensitive to potential subgroups within the at-risk, preclinical AD population (PCAD). The present study investigated the utility of asymmetric cognitive profiles in identifying individuals at risk for AD. Twenty elderly adults who were later diagnosed with AD (PCAD) and 20 matched control participants were compared on measures of cognitive asymmetry derived from difference scores on tests of verbal and visuospatial ability. Although both groups performed similarly on the individual tests, comparisons using difference scores revealed significantly larger discrepancies between naming and visuoconstruction skills in the PCAD group. The PCAD group also had a higher frequency of asymmetric cognitive profiles relative to a normative group.

Entities:  

Mesh:

Year:  2002        PMID: 11949704     DOI: 10.1037//0894-4105.16.2.132

Source DB:  PubMed          Journal:  Neuropsychology        ISSN: 0894-4105            Impact factor:   3.295


  24 in total

1.  Cross-Disorder Cognitive Impairments in Youth Referred for Neuropsychiatric Evaluation.

Authors:  Alysa E Doyle; Pieter J Vuijk; Nathan D Doty; Lauren M McGrath; Brian L Willoughby; Ellen H O'Donnell; H Kent Wilson; Mary K Colvin; Deanna C Toner; Kelsey E Hudson; Jessica E Blais; Hillary L Ditmars; Stephen V Faraone; Larry J Seidman; Ellen B Braaten
Journal:  J Int Neuropsychol Soc       Date:  2017-08-04       Impact factor: 2.892

2.  Asymmetry in auditory and spatial attention span in normal elderly genetically at risk for Alzheimer's disease.

Authors:  Mark W Jacobson; Dean C Delis; Mark W Bondi; David P Salmon
Journal:  J Clin Exp Neuropsychol       Date:  2005-02       Impact factor: 2.475

Review 3.  Neuropsychological and neuroimaging changes in preclinical Alzheimer's disease.

Authors:  Elizabeth W Twamley; Susan A Legendre Ropacki; Mark W Bondi
Journal:  J Int Neuropsychol Soc       Date:  2006-09       Impact factor: 2.892

Review 4.  Neuropsychological contributions to the early identification of Alzheimer's disease.

Authors:  Mark W Bondi; Amy J Jak; Lisa Delano-Wood; Mark W Jacobson; Dean C Delis; David P Salmon
Journal:  Neuropsychol Rev       Date:  2008-03-18       Impact factor: 7.444

Review 5.  Neuropsychological assessment of dementia.

Authors:  David P Salmon; Mark W Bondi
Journal:  Annu Rev Psychol       Date:  2009       Impact factor: 24.137

6.  Discrepancies between cognition and decision making in older adults.

Authors:  S Duke Han; Patricia A Boyle; Bryan D James; Lei Yu; Lisa L Barnes; David A Bennett
Journal:  Aging Clin Exp Res       Date:  2015-05-21       Impact factor: 3.636

7.  Normative Data for Derived Measures and Discrepancy Scores for the Uniform Data Set 3.0 Neuropsychological Battery.

Authors:  Paulina V Devora; Samantha Beevers; Andrew M Kiselica; Jared F Benge
Journal:  Arch Clin Neuropsychol       Date:  2019-01-24       Impact factor: 2.813

Review 8.  Use of functional magnetic resonance imaging in the early identification of Alzheimer's disease.

Authors:  Christina E Wierenga; Mark W Bondi
Journal:  Neuropsychol Rev       Date:  2007-05-03       Impact factor: 7.444

Review 9.  Cognitive phenotypes, brain morphometry and the detection of cognitive decline in preclinical AD.

Authors:  Mark W Jacobson; Linda K McEvoy; Anders Dale; Christine Fennema-Notestine
Journal:  Behav Neurol       Date:  2009       Impact factor: 3.342

10.  The emergence of cognitive discrepancies in preclinical Alzheimer's disease: a six-year case study.

Authors:  Mark W Jacobson; Dean C Delis; Guerry M Peavy; Spencer R Wetter; Erin D Bigler; Tracy J Abildskov; Mark W Bondi; David P Salmon
Journal:  Neurocase       Date:  2009-04-21       Impact factor: 0.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.